Investment Considerations Mydecine’s portfolio includes a robust line of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates. The company has an exclusive partnership with Applied Pharmaceutical Innovation providing access to world-class, end-to-end drug development infrastructure under one roof. Mydecine’s management team features highly experienced … Continue reading “Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA)”